Human mass balance, metabolite profile and identification of metabolic enzymes of [14C]ASP015K, a novel oral janus kinase inhibitor

Xenobiotica

Volumn 45, Issue 10, 2015, Pages 887-902

  Oda, Kazuo ^a   Cao, Ying J ^b   Sawamoto, Taiji ^a   Nakada, Naoyuki ^a   Fisniku, Ogert ^b   Nagasaka, Yasuhisa ^a   Sohda, Kin Ya ^a  

^a ASTELLAS PHARMA INC   (Japan)

^b ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

ASP015K; human mass balance study; liver cytosols; metabolic enzyme

Indexed keywords

AS 2604202; AS 2628528; AS 2645866; CARBON 14; DRUG METABOLITE; NICOTINAMIDE; NICOTINAMIDE METHYLTRANSFERASE; PEFICITINIB; SULFOTRANSFERASE; SULFOTRANSFERASE 2A1; UNCLASSIFIED DRUG; 4-((5-HYDROXY-2-ADAMANTYL)AMINO)-1H-PYRROLO(2,3-B)PYRIDINE-5-CARBOXAMIDE; ADAMANTANE; ALCOHOL SULFOTRANSFERASE; CARBON; JANUS KINASE; NNMT PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ADULT; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CYTOSOL; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ELIMINATION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG METABOLISM; DRUG TOLERABILITY; DRUG URINE LEVEL; ELIMINATION HALF-LIFE; ELIMINATION RATE CONSTANT; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; INTRINSIC CLEARANCE; ISOTOPE LABELING; LIVER CELL; MALE; MAXIMUM PLASMA CONCENTRATION; METABOLIC CLEARANCE; OPEN STUDY; PLASMA CONCENTRATION-TIME CURVE; RADIOACTIVITY; RENAL CLEARANCE; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; ADOLESCENT; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BLOOD; FECES; GENETICS; METABOLIC CLEARANCE RATE; METABOLISM; METHYLATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; URINE; YOUNG ADULT;

ADAMANTANE; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; CARBON RADIOISOTOPES; FECES; HUMANS; JANUS KINASES; MALE; METABOLIC CLEARANCE RATE; METHYLATION; MIDDLE AGED; NIACINAMIDE; NICOTINAMIDE N-METHYLTRANSFERASE; PROTEIN KINASE INHIBITORS; SULFOTRANSFERASES; YOUNG ADULT;

EID: 84940473327     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2015.1026864     Document Type: Article

References (25)

1. Aksoy IA, Sochorová V, Weinshilboum RM. (1993). Human liver dehydroepiandrosterone sulfotransferase: nature and extent of individual variation. Clin Pharmacol Ther 54:498-506.
2. Chen NC, Yang F, Capecci LM, et al. (2010). Regulation of homocysteine metabolism and methylation in human and mouse tissues. FASEB J 24:2804-17.
3. Chiba K, Saitoh A, Koyama E, et al. (1994). The role of S-mephenytoin 40-hydroxylase in imipramine metabolism by human liver microsomes: a two-enzyme kinetic analysis of N-demethylation and 2-hydroxylation. Br J Clin Pharmacol 37:237-42.
4. Cubitt HE, Houston JB, Galetin A. (2011). Prediction of human drug clearance by multiple metabolic pathways: integration of hepatic and intestinal microsomal and cytosolic data. Drug Metab Dispos 39: 864-73.
5. Emanuelli M, Cecati M, Sartini D, Pozzi V. (2010). NNMT (nicotinamide N-methyltransferase). Atlas Genet Cytogenet Oncol Haematol 14:570-7.
6. Hanano M, Umemura K, Iga T. (1985). Applied pharmacokinetics-theory and experiments. Tokyo, Japan: Soft Science, Inc.
7. Higashi Y, Inami M, Ito M, et al. (2012). ASP015K: a novel JAK inhibitor demonstrated potent efficacy in a chronic oxazolone-induced dermatitis model in rats. Abstracts (P093) of the 3rd World Psoriasis & Psoriatic Arthritis Conference: "Psoriasis-a global health challenge".
8. Honma W, Shimada M, Sasano H, et al. (2002). Phenol sulfotransferase, ST1A3, as the main enzyme catalyzing sulfation of troglitazone in human liver. Drug Metab Dispos 30:944-9.
9. Hop CE, Wang Z, Chen Q, Kwei G. (1998). Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening J Pharm Sci 87:901-3.
10. Hoshino J, Schlüter U, Kröger H. (1984). Nicotinamide methylation and its relation to NAD synthesis in rat liver tissue culture. Biochemical basis for the physiological activities of 1-methylnicotinamide. Biochim Biophys Acta 801:250-8.
11. Imada K, Leonard WJ. (2000). The Jak-STAT pathway. Mol Immunol 37:1-11.
12. Kitagawa H, Masuzawa T, Nakamura T, Matsumoto E. (1993). A batch preparation method for graphite targets with low background for AMS 14C measurements. Radiocarbon 35:295-300.
13. Leonard WJ, Lin JX. (2000). Cytokine receptor signaling pathways. J Allergy Clin Immunol 105:877-88.
14. Nagata K, Shimada M, Yamazoe Y. (2005). Species differences in cytosolic sulfotransferases. In: Pacifici GM, Coughtrie MHW, eds. Human cytosolic sulfotransferases. Boca Raton (FL): Taylor & Francis, 253-78.
15. Oda K, Mera K, Nagasaka Y, Tokoro K. (2014). Simultaneous determination of novel oral Janus Kinase inhibitor ASP015K and sulfuric metabolite M2 concentrations in rat plasma using high-performance liquid chromatography with tandem mass spectrometric detection. Biomed Chromatogr in press.
16. Jenks BH, McKee RW, Swendseid ME, et al. (1987). Methylated niacin derivatives in plasma and urine after an oral dose of nicotinamide given to subjects fed a low-methionine diet. Am J Clin Nutr 46:496-502.
17. Pumpo R, Sarnelli G, Spinella A, et al. (2001). The metabolism of nicotinamide in human liver cirrhosis: a study on N-methylnicotinamide and 2-pyridone-5-carboxamide production. Am J Gastroenterol 96:1183-7.
18. Ring BJ, Binkley SN, Roskos L, Wrighton SA. (1995). Effect of fluoxetine, norfluoxetine, sertraline and desmethyl sertraline on human CYP3A catalyzed 10-hydroxy midazolam formation in vitro. J Pharmacol Exp Ther 275:1131-5.
19. Saito S, Iida A, Sekine A, et al. (2001). Identification of 197 genetic variations in six human methyltranferase genes in the Japanese population. J Hum Genet 46:529-37.
20. Sakuma S, Nishigaki F, Magari K, et al. (2001). FK506 is superior to methotrexate in therapeutic effects on advanced stage of rat adjuvantinduced arthritis. Inflamm Res 50:509-14.
21. Takeuchi T, Tanaka Y, Iwasaki M, et al. (2014). A phase 2b study of an oral JAK inhibitor ASP015K monotherapy in Japanese patients with moderate to severe rheumatoid arthritis. EULAR; 2014 Jun 11-14; Paris, France.
22. Teubner W, Meinl W, Florian S, et al. (2007). Identification and localization of soluble sulfotransferases in the human gastrointestinal tract. Biochem J 404:207-15.
23. Thomae BA, Eckloff BW, Freimuth RR, et al. (2002). Human sulfotransferase SULT2A1 pharmacogenetics: genotype-to-phenotype studies. Pharmacogen J 2:48-56.
24. Yamazoe Y, Kato R. (1995). Structure and function of sulphotransferases. In: Pacifici GM, Fracchia GN, eds. Advances in drug metabolism in man. Luxembourg: European Commission, 659-78.
25. Zhu T. (2012). Pharmacodynamics of ASP015K, a novel Janus kinase inhibitor, in healthy volunteers. San Diego, CA: American College of Clinical Pharmacology.